Phoenix, October 20, 2020 Amnio Technology, LLC, a global leader in the development and distribution of amniotic tissue allografts, is announcing today that it has received authorization from FDA to proceed with a Phase 2 clinical trial under an Investigational New...
PHOENIX, December 16, 2019 — Amnio Technology, LLC, a leading manufacturer of advanced regenerative allografts derived from human amniotic tissues, is honored to have been awarded MedTech Wound Care’s Top 10 Solution Providers of 2019. About Amnio Technology,...
PHOENIX, Sept. 5, 2017 /PRNewswire/ — Amnio Technology, LLC, a leading manufacturer of advanced regenerative allografts derived from human amniotic tissues, announced today the expansion of its product line with the launch of PalinGen® InovōFlo™. PalinGen®...
FOR IMMEDIATE RELEASE: Amnio Technology’s PalinGen® and ProMatrX® Lines Assigned Q Codes for Product Reimbursement Phoenix, AZ, USA (November 14, 2016) – Amnio Technology, LLC, a leading manufacturer of advanced regenerative allografts derived from human...
FOR IMMEDIATE RELEASE: Amnio Technology Announces PalinGen® and ProMatrX™ Product Coverage by Palmetto GBA Phoenix, AZ, USA (June 15, 2016) – Amnio Technology, a manufacturer and distributor of amnion-derived human allografts, announced today that Palmetto...
Amnio Technology, LLC receives its first US patent for placental tissue allograft Accelular amnion derived therapeutic compositions. Amnion derived materials continue to be evaluated for use in a wide array of clinical conditions. Amnio Technology is dedicated to...
Recent Comments